Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
Highlights from ESMO 2026
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
In this episode of Meeting Mic, we bring you pearls and perspectives from the European Society for Medical Oncology 2026 Congress.
In an interview, Susana M. Campos, MD, clinical director of the division of gynecological oncology at Dana-Farber Cancer Institute, provides an overview of highlights in ovarian cancer at the meeting.
Next, Brian M. Slomovitz, MD, MS, FACOG, director of gynecologic oncology and deputy director of Braman Comprehensive Cancer Center at Mount Sinai Medical Center in Florida, comments on results of the randomized phase 3 KEYNOTE-093 trial.
Read the full coverage here:
Chemotherapy-free option may be 'highly desired choice' for endometrial cancer subset
Slomovitz BM, et al. Abstract LBA12. Presented at: ESMO Congress; Oct. 23-27, 2026; Madrid.
Sofetabart mipitecan produces 'robust' response in platinum sensitive ovarian cancer
Kyi C, et al. Abstract 1246RO. Presented at: European Society for Medical Oncology Congress; Oct. 23-27; Madrid.
Sacituzumab tirumotecan 'new standard of care' for advanced, recurrent endometrial cancer
Lorusso D, et al. Abstract LBA11. Presented at: European Society for Medical Oncology Congress; Oct. 23-27, 2026; Madrid.
Digital app 'immensely powerful' in treating insomnia among women with cancer
Brennan D, et al. Abstract LBA91. Presented at: European Society for Medical Oncology Congress; Oct. 23-27; Madrid.
Campos reports multiple ties to industry. Slomovitz reports advisory board roles with AADI Bioscience, AstraZeneca, Eisai, Genentech, Gilead Sciences, GSK, Immunogen, Incyte, Merck, Novocure and Seagen. He also is a member of the board of directors for GOG Foundation. Please see the studies for all other authors' relevant financial disclosures.